ConductScience.org, home

Paper25242553

An engineered Axl 'decoy receptor' effectively silences the Gas6-Axl signaling axis.

Kariolis MS and 6 others. Nat Chem Biol, 2014. Cited by 126 papers, by iCite.

Cite this record

ConductScience Library. An engineered Axl 'decoy receptor' effectively silences the Gas6-Axl signaling axis. Papers, record 25242553. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/25242553

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
An engineered Axl 'decoy receptor' effectively silences the Gas6-Axl signaling axis.
PubMed
Journal
Nat Chem Biol
PubMed
Year
2014
PubMed
Publication types
Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.
PubMed
Citations, by iCite
126
iCite
Relative citation ratio, by iCite
3.18
iCite
Revised in PubMed
2026-11-02
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Kariolis MSMihalis S
2Miao YRYu Rebecca
3Jones DS 2ndDouglas S
4Kapur SShiven
5Mathews IIIrimpan I
6Giaccia AJAmato J
7Cochran JRJennifer R

Source PubMed

Download CSV of authors

Topics21

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Genetic EngineeringMajor topic
Immunoglobulin Fc FragmentsMajor topic
Intercellular Signaling Peptides and ProteinsMajor topic
Proto-Oncogene ProteinsMajor topic
Receptor Protein-Tyrosine KinasesMajor topic
Signal TransductionMajor topic
Animals
Binding Sites
Disease Progression
Dose-Response Relationship, Drug
Humans
Mice
Models, Molecular
Mutation
Neoplasm Metastasis
Neoplasms, Experimental
Protein Binding
Recombinant Fusion Proteins
Structure-Activity Relationship
Axl Receptor Tyrosine Kinase
Growth Arrest-Specific Protein 6

Source PubMed

Download CSV of topics

Grants6

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
P30 CA124435NCI NIH HHSUnited StatesP30CA124435PubMed and NIHNIH RePORTER
R37 CA088480NCI NIH HHSUnited StatesR01CA088480PubMed and NIHNIH RePORTER
CA-088480NCI NIH HHSUnited StatesR01CA088480PubMed and NIHNIH RePORTER
CA-67166NCI NIH HHSUnited StatesP01CA067166PubMed and NIHNIH RePORTER
R37CA088480NIHNIH RePORTER
T32GM008412NIHNIH RePORTER

Download CSV of grants

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT05346536Liquid Biopsy and Pancreas Cancer: Detection of AXL(+) CTCs (CTC-AXL-PANC)Background

Source ClinicalTrials.gov

Download CSV of trials

References45

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
120080645Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival.Proc Natl Acad Sci U S A2010https://conductscience.org/library/papers/20080645PubMed
219633687Axl as a potential therapeutic target in cancer: role of Axl in tumor growth, metastasis and angiogenesis.Oncogene2009https://conductscience.org/library/papers/19633687PubMed
315299926Refinement of macromolecular structures by the maximum-likelihood method.Acta Crystallogr D Biol Crystallogr1997https://conductscience.org/library/papers/15299926PubMed
422910292Targeting Axl with an high-affinity inhibitory aptamer.Mol Ther2012https://conductscience.org/library/papers/22910292PubMed
523921085The receptor AXL diversifies EGFR signaling and limits the response to EGFR-targeted inhibitors in triple-negative breast cancer cells.Sci Signal2013https://conductscience.org/library/papers/23921085PubMed
617064312Gas6 and protein S. Vitamin K-dependent ligands for the Axl receptor tyrosine kinase subfamily.FEBS J2006https://conductscience.org/library/papers/17064312PubMed
712218057Crystal structure of a C-terminal fragment of growth arrest-specific protein Gas6. Receptor tyrosine kinase activation by laminin G-like domains.J Biol Chem2002https://conductscience.org/library/papers/12218057PubMed
810227296Tyro-3 family receptors are essential regulators of mammalian spermatogenesis.Nature1999https://conductscience.org/library/papers/10227296PubMed
91540948Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor.Cancer Res1992https://conductscience.org/library/papers/1540948PubMed
1012676979Flexibility analysis of enzyme active sites by crystallographic temperature factors.Protein Eng2003https://conductscience.org/library/papers/12676979PubMed
1119567592Differential expression of Axl and Gas6 in renal cell carcinoma reflecting tumor advancement and survival.Clin Cancer Res2009https://conductscience.org/library/papers/19567592PubMed
128336730The protein encoded by a growth arrest-specific gene (gas6) is a new member of the vitamin K-dependent proteins related to protein S, a negative coregulator in the blood coagulation cascade.Mol Cell Biol1993https://conductscience.org/library/papers/8336730PubMed
1320057045Molecular replacement with MOLREP.Acta Crystallogr D Biol Crystallogr2010https://conductscience.org/library/papers/20057045PubMed
1415711537A small molecule-kinase interaction map for clinical kinase inhibitors.Nat Biotechnol2005https://conductscience.org/library/papers/15711537PubMed
1518421305Immunobiology of the TAM receptors.Nat Rev Immunol2008https://conductscience.org/library/papers/18421305PubMed
1623275061LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models.Invest New Drugs2013https://conductscience.org/library/papers/23275061PubMed
1718620092TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer.Adv Cancer Res2008https://conductscience.org/library/papers/18620092PubMed
1824202397Tumor metastasis: moving new biological insights into the clinic.Nat Med2013https://conductscience.org/library/papers/24202397PubMed
1916585512Dominant-negative inhibition of the Axl receptor tyrosine kinase suppresses brain tumor cell growth and invasion and prolongs survival.Proc Natl Acad Sci U S A2006https://conductscience.org/library/papers/16585512PubMed
2020145120R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer.Cancer Res2010https://conductscience.org/library/papers/20145120PubMed

See all 45 referencesDownload CSV of references

Cited by93

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 126 citations.

PMIDTitleJournalYearIn PapersSource
42860404Targeting receptor tyrosine kinases: from molecular mechanisms to clinical therapeutics.Signal Transduct Target Ther2026https://conductscience.org/library/papers/42860404PubMed
42835524AXL at the nexus of therapeutic resistance, tumor vascularization, and immune evasion in cancer.iScience2026https://conductscience.org/library/papers/42835524PubMed
42581147Molecular mechanisms, therapeutic strategies, and inter-organ fibrosis crosstalk of Gla proteins in cardiovascular disease.Commun Biol2026https://conductscience.org/library/papers/42581147PubMed
41582591RTK AXL and its Isoforms: Regulation and Implications in Cancer.Curr Med Chem2026https://conductscience.org/library/papers/41582591PubMed
41506583Laminin G domains define a critical interface for protein S-mediated factor IXa inhibition.J Thromb Haemost2026https://conductscience.org/library/papers/41506583PubMed
40813689Signaling networks and MiRNA crosstalk in ovarian cancer chemoresistance.J Ovarian Res2025https://conductscience.org/library/papers/40813689PubMed
40069722Dys-regulated phosphatidylserine externalization as a cell intrinsic immune escape mechanism in cancer.Cell Commun Signal2025https://conductscience.org/library/papers/40069722PubMed
40044635Proteolysis of TAM receptors in autoimmune diseases and cancer: what does it say to us?Cell Death Dis2025https://conductscience.org/library/papers/40044635PubMed
39879384Targeting AXL Inhibits the Growth and Metastasis of Prostate Cancer in Bone.Clin Cancer Res2025https://conductscience.org/library/papers/39879384PubMed
39537929Clinical functional proteomics of intercellular signalling in pancreatic cancer.Nature2025https://conductscience.org/library/papers/39537929PubMed
39430290Role and Mechanisms of Tyro3 in Podocyte Biology and Glomerular Disease.Kidney Dis (Basel)2024https://conductscience.org/library/papers/39430290PubMed
39367387AXL as immune regulator and therapeutic target in Acute Myeloid Leukemia: from current progress to novel strategies.Exp Hematol Oncol2024https://conductscience.org/library/papers/39367387PubMed
39062902MERTK Inhibition as a Targeted Novel Cancer Therapy.Int J Mol Sci2024https://conductscience.org/library/papers/39062902PubMed
38989559MAGPIE: An interactive tool for visualizing and analyzing protein-ligand interactions.Protein Sci2024https://conductscience.org/library/papers/38989559PubMed
38673795Tumor-Extrinsic Axl Expression Shapes an Inflammatory Microenvironment Independent of Tumor Cell Promoting Axl Signaling in Hepatocellular Carcinoma.Int J Mol Sci2024https://conductscience.org/library/papers/38673795PubMed
38616895Potential roles for efferocytosis in glioblastoma immune evasion.Neurooncol Adv2024https://conductscience.org/library/papers/38616895PubMed
38391974Signaling Pathways of AXL Receptor Tyrosine Kinase Contribute to the Pathogenetic Mechanisms of Glioblastoma.Cells2024https://conductscience.org/library/papers/38391974PubMed
38371953ACE2-Fc and DPP4-Fc decoy receptors against SARS-CoV-2 and MERS-CoV variants: a quick therapeutic option for current and future coronaviruses outbreaks.Antib Ther2024https://conductscience.org/library/papers/38371953PubMed
38276597Molecular Characterization of the Recombinant Ig1 Axl Receptor Domain: An Intriguing Bait for Screening in Drug Discovery.Molecules2024https://conductscience.org/library/papers/38276597PubMed
38092952Therapeutic targeting of the functionally elusive TAM receptor family.Nat Rev Drug Discov2024https://conductscience.org/library/papers/38092952PubMed

See all 93 cited byDownload CSV of cited by

Genes10

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data1

The data bank entries PubMed's record names. Trial numbers are under Trials.

Data bankAccession
PDB4RA0

Source PDB

Download CSV of data

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Comments and corrections
  • Drugs

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/25242553

GET https://conductscience.org/api/papers/v1/25242553/references?page=2